Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-133 in Relapsed/Refractory Malignancies
NCT02541370Phase 2Completed
- Sponsor
- Chinese PLA General Hospital
- Start
- Jun 2015
- Primary completion
- Jun 2019
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD133-CAR T cells in liver cancer, pancreatic cancer (PC), brain tumor and 5 more, sponsored by Chinese PLA General Hospital. Primary endpoint: Occurrence of study related adverse events at 24 weeks. Started Jun 2015; status: completed.
02
Drugs
CD133-CAR T cells
03
Conditions
liver cancerpancreatic cancer (PC)brain tumorbreast cancerovarian neoplasm
Beyond the preview
Go deeper on NCT02541370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02541370.